Opinion|Videos|March 18, 2025
Evolution of Oncology Pharmacy Practice in mCRC
Experts discuss how the role of oncology pharmacists in managing metastatic colorectal cancer (mCRC) has evolved, particularly in enabling medication adjustments, refills, and prescribing supportive care medications, and explore the impact of this expanded role on patient outcomes and how pharmacists can leverage medication knowledge to optimize treatment and patient care further.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has the role of oncology pharmacists in managing mCRC evolved, particularly in enabling medication adjustments, refills, and prescribing supportive care medications?
- What impact has this expanded role had on patient outcomes?
- In what ways can pharmacists leverage medication knowledge to optimize treatment and patient care for mCRC further?
Advertisement
Related to this article
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Disability, Economic Toll of Multimorbidity Climb in Older Adults
3
October FDA Approvals Bring Advances Across 5 Specialties
4
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
5